CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference, scheduled from April 12 – 15, 2021. The presentation will take place on April 14 at 4:30 pm Eastern Time. The company's lead product, DefenCath™, is designed to prevent bloodstream infections in hemodialysis patients. It has received FDA's Fast Track designation and Qualified Infectious Disease Product status, granting it extended marketing exclusivity. Visit cormedix.com for more information.

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place on April 12 – 15, 2021.

20th Annual Needham Virtual Healthcare Conference (virtual)
Date:                Wednesday, April 14^th
Time:                4:30 pm Eastern Time
Webcast:          https://wsw.com/webcast/needham107/crmd/2235068

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin^® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
617-430-7576

FAQ

What date will CorMedix present at the Needham Virtual Healthcare Conference?

CorMedix will present on April 14, 2021.

What time is CorMedix's presentation at the conference?

The presentation is scheduled for 4:30 pm Eastern Time.

What is the lead product of CorMedix?

CorMedix's lead product is DefenCath™, aimed at preventing bloodstream infections.

What designations has DefenCath™ received from the FDA?

DefenCath™ has received Fast Track designation and Qualified Infectious Disease Product status.

Where can I find more information about CorMedix?

More information can be found at their website, cormedix.com.